

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **利君國際醫藥(控股)有限公司**

**Lijun International Pharmaceutical (Holding) Co., Ltd.**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock code: 2005)**

### **POSITIVE PROFIT ALERT**

This announcement is made by the Company pursuant to Rule 13.09(2)(a) of the Listing Rules and Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors of the Company that the Group is expected to record a significant net profit for the year ended 31 December 2012 as compared to a net loss recorded in the year of 2011.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Lijun International Pharmaceutical (Holding) Company Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) of the Company and potential investors of the Company that the Group is expected to record a significant net profit for the year ended 31 December 2012 as compared to a net loss recorded in the year of 2011. This significant net profit is primarily attributable to (i) significant growth of the intravenous infusion solution business of the Group in the year of 2012 and (ii) no impairment loss being required to be recognised on goodwill for the year ended 31 December 2012 in respect of the intravenous infusion solution business of the Group

based on preliminary information received by the Board on 25 February 2013 on the valuation of the Shijiazhuang No. 4 Pharmaceutical Co., Ltd. (“**Shijiazhuang No. 4 Pharma**”). This is in contrast with a recognition of goodwill impairment loss for the year of 2011 based on a valuation report received by the Board on 23 February 2012 on the valuation of the Shijiazhuang No. 4 Pharma and as announced by the Company on the same date.

The Company is in the process of finalising the annual results of the Group for the year ended 31 December 2012 and the related audit work has not yet been completed. The information contained in this announcement is based on a preliminary assessment by the Board on the unaudited consolidated management accounts of the Group for the year ended 31 December 2012 and the information currently available, which have not been confirmed or audited by the Company’s independent auditors. The actual results for the Group may be different from what is disclosed in this announcement. Shareholders and investors should read carefully the results announcement of the Company for year ended 31 December 2012, which is expected to be published in March 2013.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Chow Hing Yeung**  
*Company Secretary*

Hong Kong, 25 February 2013

*As at the date of this announcement, the Board comprises Mr. Wu Qin, Mr. Qu Jiguang, Mr. Xie Yunfeng, Mr. Wang Xianjun and Mr. Duan Wei as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.*